Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Actemra

(ak-TEM-ruh)
A drug used to treat adults and children aged 2 years and older with severe or life-threatening cytokine release syndrome caused by a type of immunotherapy called chimeric antigen receptor (CAR) T-cell therapy. Actemra is also used to treat certain types of arthritis and a condition that causes inflammation of the lining of the arteries. It is also being studied in the treatment of other conditions. Actemra binds to receptors for a protein called interleukin-6 (IL-6), which is made by white blood cells and other cells in the body. This may help lower the body’s immune response and reduce inflammation. Actemra is a type of monoclonal antibody. Also called tocilizumab.
More Information
Search NCI's Dictionary of Cancer Terms